RxDoctor Payments Data

Shawn Sommerlad, PA

Physician Assistant · Dallas, TXNPI 1689978769

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $36,500 of the $52,648 with a category attached, or 69.3%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 82.6% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $22,958 and has fallen 92.2% since, to $1,786 in 2025. Among physician assistant clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$52,648in general payments, 2019–2025

Across 439 payments — averaging $119.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$44K
  • Abbott$4K
  • Johnson & Johnson$1K
  • Novartis$765
  • Merck$426
  • Amgen$416
  • plus $2K from 18 others

What the payments were for

  • Speaking & faculty fees$36,50069%
  • Travel & lodging$5,21910%
  • Food & beverage$10,91521%
  • Education$140%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,648 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$212,810
Medicare patients
386
Services billed
2,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$46,119
JardianceEmpagliflozin43$35,259
FarxigaDapagliflozin Propanediol29$28,965
XareltoRivaroxaban17$24,854
EntrestoSacubitril/Valsartan34$21,359
ClopidogrelClopidogrel Bisulfate125$658
Atorvastatin Calcium116$602
Lisinopril35$502
Ezetimibe16$487
Chlorthalidone26$458
Amlodipine Besylate48$395
Metoprolol Succinate35$286
Metoprolol Tartrate32$223
Spironolactone32$207
Hydralazine Hcl53$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$408$46,11953 claims
Boehringer IngelheimJardiance$124$35,25943 claims
AstraZenecaFarxiga$238$28,96529 claims
Johnson & JohnsonXarelto$1,125$24,85417 claims
NovartisEntresto$765$21,35934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →